Latest Uk Market News

OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

Harvey Norman Holdings reported a robust 39% jump in profit before tax for FY25, driven by strong franchise sales, a booming property portfolio, and strategic international expansion.

Cluey Ltd reported a significantly reduced loss for FY25 alongside an 11% increase in new students and achieved positive operating cash flow in Q4, signaling progress in its path to profitability.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

PEXA Group Ltd reported a robust FY25 with 16% revenue growth and a 21% rise in EBITDA, driven by national expansion and operational efficiencies. The company is advancing its UK platform launch backed by NatWest, while FY26 guidance signals continued growth and strategic focus on AI and resilience.

PEXA Group Limited reported a 16% revenue increase to $393.6 million for FY25, driven by growth across its Australian Exchange, UK International business, and Digital Solutions segments. Despite a statutory net loss of $76.1 million due to impairments and deferred tax derecognition, core EBITDA rose 21% with improved margins.

Pureprofile Limited reported a record FY25 with net profit after tax surging to $1.5 million, underpinned by 19% revenue growth and strategic AI product launches. The company’s global footprint expanded significantly, with international markets now accounting for nearly half of total revenue.

RAS Technology Holdings Limited reported a robust 31% increase in revenue to A$21.3 million for FY25, alongside its first net profit after tax since listing, driven by strategic acquisitions and global expansion.

Alcidion Group Limited has reported a transformative FY25 with record earnings, a major NHS contract win, and a robust outlook for FY26. The company’s healthcare technology platform is gaining traction across the UK and Australia, setting the stage for accelerated growth.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Kip McGrath Education Centres reported solid FY25 growth in revenue and EBITDA from continuing operations, marked by a strategic exit from the USA and a new share buy-back program.